THIRD QUARTER IN BRIEF Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31) Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11) Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting…
THIRD QUARTER IN BRIEF Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4) The first part of the multiple dose of laquinimod eye…
“We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer” THIRD QUARTER IN BRIEF • Active Biotech provided status update of its clinical naptumomab project on July 5• …
IMPORTANT EVENTS DURING THE THIRD QUARTERTasquinimod First patient dosed in the monotherapy part of the phase 1b/2a study in multiple myeloma The clinical study design for multiple myeloma will be presented at the virtual American Society of Hematology meeting 2020 in December Patents regarding treatment of acute leukemia granted in…
Third quarter in brief Active Biotech provides update on laquinimod in Huntington’s disease Active Biotech regains global rights to the development and commercialization of laquinimod Data from the LEGATO-HD study of laquinimod in Huntington’s disease presented at the EHDN meeting Events after the end of the period New data from…
Third quarter in brief The company’s application related to one of the patent families in the SILC project was granted patent in the US Preclinical data for a SILC substance was published in the scientific journal Cancer Immunology Research The process to divest the company’s research facility at Ideon in…
Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017 The study results from the pivotal clinical Phase 2 ARPEGGIO study, evaluating…
Laquinimod The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017 The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod’s potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington’s disease, are…
Laquinimod· Teva presented new clinical safety data in RRMS patients treated with laquinimod for two or more years at joint ACTRIMS-ECTRIMS meeting · Teva initiated clinical studies with laquinimod in primary progressive MS (PPMS) and Huntington’s disease· The ongoing US pivotal clinical study CONCERTO is continuing according to plan. Results are expected in…
Laquinimod Analysis of data from the Phase III ALLEGRO study shows that laquinimod provides a beneficial impact on brain tissue damage; Laquinimod-treated patients accumulated significantly less brain tissue damage caused by neurodegeneration New data presented at ECTRIMS shows that laquinimod has an effect on both inflammation and the underlying mechanisms…
· Laquinimod – Teva to initiate a new Phase III study in the US at year-end – milestone payment of USD 5 M received following a submitted application for regulatory approval in Europe – Crohn’s Phase II data presented at the UEGW conference · TASQ – biomarker data presented at the ESMO…
* Laquinimod – Phase III BRAVO trial concluded. Teva plans an additional clinical study before filing a registration application in the US * TASQ – enrolment of patients for Phase III trial ongoing * TASQ – Phase II trial published in Journal of Clinical Oncology * ANYARA – Phase III trial proceeding according to…
* Laquinimod ― Phase III trials proceeding as planned, results from Phase II extension study published in scientific journal * TASQ ― preparations ongoing for start of Phase III in first half of 2011 * ANYARA ― ongoing phase III trial expected to be concluded in first half of 2012…
